Statin use and lower extremity amputation risk in nonelderly diabetic patients

Journal of Vascular Surgery

Volumn 58, Issue 6, 2013, Pages

  Sohn, Min Woong ^a,b   Meadows, Judith L ^b   Oh, Elissa H ^b   Budiman Mak, Elly ^a,c   Lee, Todd A ^a,d   Stone, Neil J ^b   Pearce, William B ^b  

^a HINES VA HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; BODY MASS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG TREATMENT FAILURE; FEMALE; FOOT ULCER; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEG AMPUTATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

EID: 84888319368     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2013.06.069     Document Type: Article

References (28)

1. M.H. Criqui, R.D. Langer, A. Fronek, H.S. Feigelson, M.R. Klauber, and T.J. McCann Mortality over a period of 10 years in patients with peripheral arterial disease N Engl J Med 326 1992 381 386
2. A.T. Hirsch, Z.J. Haskal, N.R. Hertzer, C.W. Bakal, M.A. Creager, and J.L. Halperin ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) Circulation 113 2006 e463 e654
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
4. R. Collins, J. Armitage, S. Parish, P. Sleigh, and R. Peto MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
5. P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, and R. Peto Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
6. D.R. Miller, M.M. Safford, and L.M. Pogach Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data Diabetes Care 27 Suppl 2 2004 B10 B21
7. M.W. Sohn, N. Arnold, C. Maynard, and D.M. Hynes Accuracy and completeness of mortality data in the Department of Veterans Affairs Popul Health Metr 4 2006 2
8. V. Bittner, R. Hardison, S.F. Kelsey, B.H. Weiner, A.K. Jacobs, and G. Sopko Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 106 2002 2537 2542
9. National Research Council of the National Academies The Prevention and Treatment of Missing Data in Clinical Trials 2010 The National Academies Press Washington, DC
10. X. Zhang, M.J. Zhang, and J. Fine A proportional hazards regression model for the subdistribution with right-censored and left-truncated competing risks data Stat Med 30 2011 1933 1951
11. J.M. Satagopan, L. Ben-Porat, M. Berwick, M. Robson, D. Kutler, and A.D. Auerbach A note on competing risks in survival data analysis Br J Cancer 91 2004 1229 1235
12. Adult Treatment Panel III, National Institute of Health. Third Report of the National Cholesterol Education Program Expert Panel and Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; 2006. Available at: http://www.nhlbi.nih.gov/cholesterol/atp3full.pdf. Accessed July 25, 2013.
13. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
14. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, and S.J. Livingstone Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
16. E. de Groot, J.W. Jukema, A.D. Montauban van Swijndregt, A.H. Zwinderman, R.G. Ackerstaff, and A.F. van der Steen B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS) J Am Coll Cardiol 31 1998 1561 1567
17. M.M. McDermott, J.M. Guralnik, P. Greenland, W.H. Pearce, M.H. Criqui, and K. Liu Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease Circulation 107 2003 757 761
18. J. Giri, M.M. McDermott, P. Greenland, J.M. Guralnik, M.H. Criqui, and K. Liu Statin use and functional decline in patients with and without peripheral arterial disease J Am Coll Cardiol 47 2006 998 1004
19. T.R. Pedersen, J. Kjekshus, K. Pyorala, A.G. Olsson, T.J. Cook, and T.A. Musliner Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S) Am J Cardiol 81 1998 333 335
20. M.W. Sohn, R.M. Stuck, M. Pinzur, T.A. Lee, and E. Budiman-Mak Lower-extremity amputation risk after charcot arthropathy and diabetic foot ulcer Diabetes Care 33 2010 98 100
21. L.A. Leiter The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res Clin Pract 68 Suppl 2 2005 S3 S14
22. M. Aikawa Effects of statin therapy on vascular dysfunction Coron Artery Dis 15 2004 227 233
23. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
24. R.J. Glynn, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med 360 2009 1851 1861
25. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, and M.R. Taskinen Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
26. K. Rajamani, P.G. Colman, L.P. Li, J.D. Best, M. Voysey, and M.C. D'Emden Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial Lancet 373 2009 1780 1788
27. M. Li, K.L. Ong, H.F. Tse, and B.M. Cheung Utilization of lipid lowering medications among adults in the United States 1999-2006 Atherosclerosis 208 2010 456 460
28. A.T. Hirsch, M.H. Criqui, D. Treat-Jacobson, J.G. Regensteiner, M.A. Creager, and J.W. Olin Peripheral arterial disease detection, awareness, and treatment in primary care JAMA 286 2001 1317 1324